优化中低收入国家输血依赖型地中海贫血同胞供者移植的可及性与结局
该研究纳入176例输血依赖型地中海贫血儿童,在亚洲和中东多中心接受基于WHO基本药物清单的简化低成本同胞供者骨髓移植。中位随访11.3个月,植入率97.3%,无地中海贫血生存率93.4%,总生存率96%,中重度急性GVHD发生率3.9%。该方案在经验丰富和新建立的移植中心同样有效。
要点
- 简化低成本方案采用氟达拉滨、地塞米松、白消安和环磷酰胺,适用于资源有限地区。
- 植入率97.3%,无地中海贫血生存率93.4%,总生存率96%,中重度急性GVHD仅3.9%。
- 该方案在经验丰富与新建立移植中心疗效相当,CMV再激活率19.2%。
核心结论
- 使用广泛可及药物的简化、安全且成本可控的移植方案可在低资源地区为重型地中海贫血儿童取得优异结局。
研究设计与样本
- 多中心研究,纳入2022年2月至2025年11月亚洲和中东多个中心176例输血依赖型地中海贫血儿童,接受同胞供者骨髓移植。
主要发现
- 植入率97.3%,中位随访11.3个月时无地中海贫血生存率93.4%,总生存率96%。
- 中重度急性GVHD发生率3.9%,无GVHD且无地中海贫血的复合实际结局为93.4%。
- CMV再激活率19.2%,仅1例(0.6%)进展为CMV疾病。
- 该方案在经验丰富和新建立的移植中心同样有效。
关键数值与推荐
- 预处理方案包括氟达拉滨、地塞米松、白消安和环磷酰胺,所用药物列于世界卫生组织基本药物清单。
- 移植物来源为粒细胞集落刺激因子动员的骨髓,GVHD预防采用环孢素联合甲氨蝶呤。
临床怎么用
- 在低资源地区可采用基于基本药物的简化同胞供者骨髓移植方案治疗输血依赖型地中海贫血儿童。
- 该方案在经验丰富和新建立的移植中心均可实施,但需关注CMV再激活。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe thalassemia (ST) is a life-threatening condition common in many low- and middle-income countries. Although bone marrow transplantation (BMT) offers a curative option, its accessibility remains limited because of cost and complexity. This study describes a simplified approach to BMT for hemoglobinopathies that is based on relatively common and inexpensive medicines. This study included 176 pediatric patients with transfusion-dependent thalassemia who received a matched sibling BMT between February 2022 and November 2025 across several centers in Asia and the Middle East. A simplified and low-cost transplant protocol was used, using drugs that are widely available and are listed in the World Health Organization Model List of Essential Medicines. The regimen included fludarabine, dexamethasone, busulfan, and cyclophosphamide. granulocyte colony-stimulating factor-primed bone marrow was used as the graft source, and graft-versus-host disease (GVHD) prophylaxis included cyclosporine and methotrexate. Rejection, mixed-chimerism rates, transplant-related mortality, and GVHD-free, overall survival, and disease-free survival composite outcomes were analyzed. Engraftment was obtained in 97.3% of patients. Thalassemia-free survival was 93.4%, and overall survival was 96%, at a median follow-up of 11.3 months. Rates of moderate to severe acute GVHD were low (3.9%) for a GVHD-free and thalassemia-free composite actuarial outcome of 93.4%. Cytomegalovirus (CMV) reactivation was observed in 19.2% of patients and 1 (0.6%) patient progressed to CMV disease. The approach was equally effective in experienced and newly established transplant centers. A simple, safe, and cost-conscious transplant approach using widely available medicines can achieve excellent outcomes for children with ST in low-resource settings.
引用
- Reddy M, Sridhar T, Mayur V, et al. Optimizing outcomes and accessibility of matched sibling donor transplant for transfusion-dependent thalassemia in LMICs. Blood Adv. 2026. PMID: 42469166. doi:10.1182/bloodadvances.2025019083
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。